You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1290267 |
---|---|
Category | Antibodies |
Description | Rituximab biosimilar antibody |
Species/Host | Mouse |
Clonality | Monoclonal |
Tested applications | FC |
Reactivity | Chimeric |
CAS Number | 174722-31-7 |
Isotype | IgG1-kappa |
Antibody Type | Biosimilar Antibody |
Purity | > 95% |
Conjugation | Unconjugated |
Target | MS4A1 |
Source | CHO cells |
Biological Activity | Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Buffer/Preservatives | PBS buffer pH 7.5 |
Alternative names | IDEC-C2B8 Read more... |
Note | For research use only |
Expiration Date | 12 months from date of receipt. |
FACS, IF, IHC-P, WB | |
Human, Mouse, Rat | |
Mouse | |
Monoclonal | |
Unconjugated |